Vir Biotechnology, Inc. (VIR)

NASDAQ • Healthcare

$10.55

+$0.11 (+1.1%)

Market closed

Last close at September 16, 2026 at 20:00 UTC

Open$10.54

Day Range$10.39 - $10.66

Avg. Volume (3M)2M

Market Cap$1.7B

52 Week Range

$4.78$11.94

Next EarningsIn 49 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$238.9M100%

Gross Profitminus cost of goods$238.9M100%

Operating Incomeminus R&D and overhead$73.4M31%

Net Incomeminus taxes and the rest$80M34%

In plain terms: out of every $100 in revenue, Vir Biotechnology, Inc. keeps $34 as net profit.

Fundamentals & Financials

Revenue (TTM)

$303.2M

Net Income (TTM)

-$251.6M

EPS (TTM)

-$1.85

ROA (TTM)

-20.72%

Current Ratio

6.04

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-11.1%Q3 2025-$0.8

-67.1%Q4 2025-$1.17

+26.2%Q1 2026-$0.31

-8400.0%Q2 2026-$0.85

+41.3%Q3 2026$0.47

Nov 4

in 49 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +41.3%

Vir Biotechnology’s revenue fell year over year in the second fiscal quarter of 2026, which it reported on August 5, 2026, as the company continued to focus on its antibody and infectious-disease medicines portfolio led by Sotrovimab (Xevudy) alongside pipeline programs in hepatitis B, influenza A, and HIV. Operating cash flow was negative at roughly -$9.1 million, reflecting cash use during the period. For the next period, consensus calls for EPS of -$0.74 on revenue of $865,125.00.

View full earnings history

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc. develops antibody and infectious-disease medicines and is listed on the NASDAQ Global Select Market under the ticker VIR. The company operates in biotechnology within healthcare, with FY2025 revenue of $68.6 million, and its commercial identity centers on Sotrovimab, marketed as Xevudy for SARS-CoV-2 treatment and prevention.

Name

Vir Biotechnology, Inc.

CEO

Marianne De Backer

Website

www.vir.bio

Industry

Healthcare

Year Founded

2016

Employees

367

Today's Snapshot

AI-generated

The day ended with VIR 1.1% higher at 10.55, while its sector was flat.

Trading Volume

Below 10d avg (2.0M)

1.9M

vs S&P 500 Today

Outperforming Market

+1.63%

Updated: September 16, 2026 at 20:02 UTC

Technical Indicators

3 Buy3 Neutral2 Sell

VIR is trading just above its classic pivot while short-term moving averages sit above the current price, indicating near-term pressure even as the stock remains supported by longer-term averages around the 50–200 day levels. Momentum measures are mixed: MACD and RSI are essentially neutral while a short-term momentum indicator is negative, and Williams %R is signaling a buy; ADX around the mid-20s points to only modest trend strength. Volatility is moderate at roughly a five percent ATR and on-balance volume shows distribution. Technical takeaway: Overall technicals favor a Buy stance.

All signals